PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Crohn's disease

Drugs in development · updated 30 October 2026

Crohn's disease: drugs in development

As of 30 October 2026 there are 84 active clinical trials (recruiting or ongoing, phases I–III) on 81 drugs for Crohn's disease. 39 are experimental, that is not yet approved in the United States.

84Active trials
39Experimental drugs
4Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
DuvakitugIII2NCT07184944
JNJ-78934804III2NCT07577843
TulisokibartIII2NCT06651281
IL-23III1NCT06274554
ZasocitinibTAK-279II3NCT06233461
AZD7798II2NCT06681324
LY4395089II2NCT07483073
TrosunilimabII2NCT07697456
ABBV-701II1NCT07697456
ABBV-8736II1NCT06548542
Adalimumab-680LTI–II1NCT07258641
AfimkibartII1NCT05910528
BrivekimigII1NCT06958536
H021II1NCT07677514
ICG318I–II1NCT07544160
IL-15I–II1NCT07544160
LutikizumabII1NCT06548542
MORF-057II1NCT06226883
MT-201II1NCT07113522
MT-501II1NCT07113522
MTP-101CII1NCT06631586
MTP-101SII1NCT06631586
N-AcetylglucosamineII1NCT07225998
ObefazimodABX464II1NCT06456593
SL-325II1NCT07753850
TRA16II1NCT07871669
TRX103I–II1NCT06721962
XanthohumolII1NCT04590508
BCD-261I1NCT06715540
BDHK-2009I1NCT07632573
CM551I1NCT07900945
FluoropyrimidineI1NCT03816345
GSK4528287I1NCT06681181
LMT503I1NCT05659953
PALI-2108I1NCT07428096
R-3750I1NCT07791888
XylitolD-xylitolI1NCT05852587
Coenzyme Q10CoQ10Early I1NCT06419335
Ga68-FAPI-46Early I1NCT07273188

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
GuselkumabTremfyaII–III8NCT03466411
RisankizumabSKYRIZIIII8NCT05995353
VedolizumabEntyvio®III8NCT06405087
MirikizumabOmvoh®III6NCT05509777
UstekinumabPyzchiva®, Starjemza®II–III6NCT03466411
UpadacitinibRinvoq Lq®, Rinvoq®III3NCT06332534
InfliximabZymfentra®, Avsola®II–III2NCT05660746
TirzepatideZepbound, MounjaroIII2NCT06937099
BudesonideTarpeyo®, Eohilia®II–III1NCT06719622
FluconazoleDiflucan®, Diflucan In Dextrose 5% In Plastic Container®III1NCT06274554
IcotrokinraIcotyde®II–III1NCT07196722
OmeprazolePrilosec®, Prilosec Otc®II–III1NCT06719622
CyclophosphamideCyclophosphamid, CytoxanI–II4NCT04224558
MelphalanEvomela®, Hepzato®I–II3NCT00692939
MethylprednisoloneMethylprednisolon, MethylprenisoloneI–II3NCT04224558

Sorted by most advanced phase and number of active trials. Showing 15 of 42 drugs.

All 81 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003424 “Crohn Disease”.

ItalianoFrançaisDeutsch